AutoCyte Moves One Step Closer To FDA Approval

AutoCyte needs FDA decision to become newest competitor in automated cytology

CEO SUMMARY: Until now, AutoCyte has kept a relatively quiet presence in the automated cytology marketplace. That may soon change as the FDA takes action on the company’s PREP™ and SCREEN™ products. AutoCyte expects these products will boost productivity and quality in cytology labs. AutoCyte’s product positioning will be very different than its competitors: NeoPath,

Subscriber-Only Content. Please Log In.

You are trying to access subscribers-only content. If you are a subscriber, please log in.

If you are not a subscriber, click here to see subscription offers.

Subscribers will have instant access to the Dark Report library, 1997 - the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!

To read our FREE article previews, go to The Dark Report Insider.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Enter Your Login Credentials
This setting should only be used on your home or work computer.

×

Send this to friend